Lataa...

Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)

BACKGROUND: The major clinical obstacle that limits the long-term benefits of treatment with osimertinib (AZD9291 or TAGRISSO™) in patients with EGFR-mutant non-small cell lung cancer (NSCLC) is the development of acquired resistance. Therefore, effective strategies that can overcome osimertinib acq...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer
Päätekijät: Zang, Hongjing, Qian, Guoqing, Zong, Dan, Fan, Songqing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Sun, Shi-Yong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7241261/
https://ncbi.nlm.nih.gov/pubmed/31999837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32744
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!